| Literature DB >> 24910389 |
Yingqiu Xie1, Shenji Liu1, Wenfu Lu1, Qing Yang1, Kieosha D Williams2, Awadh A Binhazim3, Brett S Carver4, Robert J Matusik5, Zhenbang Chen6.
Abstract
SLUG represses E-cadherin to promote epithelial-mesenchymal transition (EMT) in various cancers. Mechanisms that regulate SLUG/E-cadherin pathway remain poorly understood, especially during tumorigenesis in vivo. Here we report that p19(Arf) (p14(ARF) in human) stabilizes Slug to inhibit E-cadherin in prostate cancer mouse models. Inactivation of p19(Arf) reduces Slug levels, resulting in increased E-cadherin expression and delaying the onset and progression of prostate cancer in Pten/Trp53 double null mice. Mechanistically, p14(ARF) stabilizes SLUG through increased sumoylation at lysine residue 192. Importantly, levels of SLUG and p14(ARF) are positively correlated in human prostate cancer specimens. These data demonstrated that ARF modulates the SLUG/E-cadherin signaling axis for augmenting prostate tumorigenesis in vivo, revealing a novel paradigm where the oncogenic functions of SLUG require ARF to target E-cadherin in prostate cancer. Collectively, our findings further support that ARF has dual tumor suppressive/oncogenic roles in cancers in a context-dependent manner.Entities:
Keywords: Mouse model; Prostate cancer; SLUG; SUMO1
Mesh:
Substances:
Year: 2014 PMID: 24910389 PMCID: PMC4198473 DOI: 10.1016/j.molonc.2014.05.006
Source DB: PubMed Journal: Mol Oncol ISSN: 1574-7891 Impact factor: 6.603